Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal
Overview
publication venue for
-
Paradoxical immune reconstitution inflammatory syndrome associated with rituximab-containing regimen in a patient with lymphoma.
2013
-
Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft.
2011
-
Seizures and radionecrosis from non-small-cell lung cancer presenting as increased fluorodeoxyglucose uptake on positron emission tomography.
2011
-
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
2009
-
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
2006
-
Aromatase inhibitor withdrawal response in metastatic breast cancer.
2006
-
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
2024
-
Vaccination of Adults With Cancer: ASCO Guideline.
2024
-
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
2024
-
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.
2024
-
Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma..
42.
2024
-
Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.
2024
-
CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition.
2023
-
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
2023
-
Myths and Presumptions About Cancer Survivorship..
42.
2023
-
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591.
2023
-
Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial..
42.
2023
-
Reply to F. Dossa et al..
42.
2023
-
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
2023
-
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.
2023
-
Pan-Cancer Analysis of Postdiagnosis Exercise and Mortality..
41.
2023
-
Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficien cy in Pancreatic Acinar Cell Carcinoma.
2023
-
Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
2023
-
Market, Gift, Everyday Ethics, and Emmanuel Levinas in Patient Care.
2023
-
Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare..
41.
2023
-
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)..
41.
2023
-
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
2023
-
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100..
41.
2023
-
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
2023
-
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
2023
-
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
2023
-
DPYD Testing: Time to Put Patient Safety First.
2023
-
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
2023
-
Racism Does Not Cause Prostate Cancer, It Causes Prostate Cancer Death.
2023
-
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
2023
-
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma..
41.
2023
-
Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study..
41.
2022
-
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials..
41.
2022
-
Molecular Classification of Appendiceal Adenocarcinoma..
41.
2022
-
Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)..
41.
2022
-
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
2022
-
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.
2022
-
Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial - ECOG-ACRIN EA6134.
2022
-
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
2022
-
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
2022
-
Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice.
2022
-
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis..
40.
2022
-
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials..
41.
2022
-
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
2022
-
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study..
40.
2022
-
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
2022
-
Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update..
40.
2022
-
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update..
40.
2022
-
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy..
40.
2022
-
Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy.
2022
-
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update..
40.
2022
-
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.
2022
-
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
2022
-
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion..
40.
2022
-
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial..
40.
2022
-
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
2021
-
Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy..
40.
2021
-
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies..
40.
2021
-
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma..
40.
2021
-
Venetoclax in Previously Treated Waldenström Macroglobulinemia..
40.
2021
-
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study..
39.
2021
-
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes.
2021
-
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
2021
-
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma..
39.
2021
-
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
2021
-
Therapeutic Implications of Germline Testing in Patients With Advanced Cancers..
39.
2021
-
Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score..
39.
2021
-
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial..
39.
2021
-
Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts.
2021
-
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study..
39.
2021
-
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer..
39.
2021
-
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)..
39.
2021
-
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma..
39.
2021
-
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors..
39.
2021
-
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)..
39.
2021
-
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412..
39.
2021
-
Burkitt Lymphoma International Prognostic Index..
39.
2021
-
Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline..
39.
2021
-
Beyond a Child's Question: Physicians and the Existential Unknown in End-of-Life Care..
39.
2021
-
Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer..
39.
2021
-
Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression..
39.
2020
-
B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study..
38.
2020
-
COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study..
38.
2020
-
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma..
39.
2020
-
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib..
38.
2020
-
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001..
38.
2020
-
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma..
38.
2020
-
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study..
38.
2020
-
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma..
38.
2020
-
Quest for Clinically Effective RAF Dimer Inhibitors..
38.
2020
-
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study..
38.
2020
-
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma..
38.
2020
-
State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach..
38.
2020
-
Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors..
38.
2020
-
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade..
38.
2020
-
Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening..
38.
2020
-
Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling..
38.
2020
-
ASCO Clinical Practice Guideline Endorsements and Adaptations..
38.
2019
-
Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline..
38.
2019
-
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer..
38.
2019
-
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease..
38.
2019
-
Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221)..
38.
2019
-
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade..
37.
2019
-
PD-1 Blockade in Advanced Adrenocortical Carcinoma..
38.
2019
-
Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study..
37.
2019
-
Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia..
37.
2019
-
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma..
37.
2019
-
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer..
37.
2019
-
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy..
37.
2019
-
Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors..
37.
2019
-
Treatment Outcomes of Immune-Related Cutaneous Adverse Events..
37.
2019
-
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline..
37.
2019
-
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx..
37.
2019
-
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia..
37.
2019
-
Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study..
37.
2019
-
Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia..
37.
2019
-
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303..
37.
2019
-
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma..
37.
2019
-
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma..
37.
2019
-
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study..
37.
2019
-
TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer..
37.
2019
-
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial..
37.
2019
-
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma..
37.
2019
-
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial..
37.
2019
-
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers..
37.
2019
-
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes..
37.
2018
-
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202..
37.
2018
-
Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?.
37.
2018
-
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2..
37.
2018
-
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer..
37.
2018
-
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer..
37.
2018
-
Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial..
36.
2018
-
Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.
2018
-
Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline..
36.
2018
-
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer..
36.
2018
-
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study..
36.
2018
-
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer..
36.
2018
-
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study..
36.
2018
-
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update..
36.
2018
-
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer..
36.
2018
-
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas..
36.
2018
-
Financial Impact of Breast Cancer in Black Versus White Women..
36.
2018
-
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials..
35.
2018
-
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study..
36.
2018
-
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers..
36.
2018
-
Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out..
36.
2018
-
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial..
36.
2018
-
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer..
36.
2018
-
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016..
36.
2018
-
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy..
36.
2018
-
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing..
36.
2018
-
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma..
36.
2017
-
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma..
36.
2017
-
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group..
35.
2017
-
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group..
35.
2017
-
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma..
35.
2017
-
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma..
35.
2017
-
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma..
35.
2017
-
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm..
35.
2017
-
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update..
35.
2017
-
Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma..
35.
2017
-
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas..
35.
2017
-
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer..
35.
2017
-
HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma..
35.
2017
-
KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation..
35.
2017
-
AKT Inhibition in Solid Tumors With AKT1 Mutations..
35.
2017
-
Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis..
35.
2017
-
American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations..
35.
2017
-
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study..
35.
2017
-
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents..
35.
2017
-
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study..
35.
2017
-
Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation..
35.
2017
-
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer..
35.
2017
-
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry..
35.
2017
-
Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy..
35.
2017
-
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes..
35.
2017
-
Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis..
35.
2017
-
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study..
35.
2016
-
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study..
35.
2016
-
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial..
35.
2016
-
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma..
35.
2016
-
Cautionary Note on Using Cross-Validation for Molecular Classification..
34.
2016
-
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma..
34.
2016
-
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma..
34.
2016
-
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis..
35.
2016
-
Protein Intake and Breast Cancer Survival in the Nurses' Health Study..
35.
2016
-
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression..
34.
2016
-
Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non-Small-Cell Lung Cancer: A Competing Risks Analysis..
35.
2016
-
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer..
34.
2016
-
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors..
34.
2016
-
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma..
34.
2016
-
Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy..
34.
2016
-
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors..
34.
2016
-
Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing..
34.
2016
-
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors..
34.
2016
-
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy..
35.
2016
-
Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival..
34.
2016
-
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma..
34.
2016
-
Characteristics of Patients Who Survived < 3 Months or > 2 Years After Surgery for Spinal Metastases: Can We Avoid Inappropriate Patient Selection?.
34.
2016
-
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers..
34.
2016
-
Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study..
34.
2016
-
Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer..
34.
2016
-
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma..
34.
2016
-
Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer..
34.
2016
-
Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers..
34.
2016
-
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study..
34.
2016
-
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer..
34.
2016
-
Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis..
34.
2016
-
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer..
34.
2016
-
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis..
34.
2016
-
Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline..
34.
2016
-
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received..
34.
2016
-
Discussions of Life Expectancy and Changes in Illness Understanding in Patients With Advanced Cancer..
34.
2016
-
Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer..
34.
2016
-
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study..
34.
2016
-
Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors..
34.
2016
-
Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer..
34.
2016
-
Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid..
34.
2016
-
Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer..
34.
2016
-
Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer..
34.
2016
-
KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma..
34.
2016
-
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816..
34.
2016
-
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy..
34.
2016
-
Cancer and Fertility Program Improves Patient Satisfaction With Information Received..
34.
2016
-
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome..
34.
2016
-
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels..
34.
2016
-
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013..
34.
2016
-
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma..
34.
2016
-
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial..
34.
2016
-
Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement..
34.
2016
-
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction..
34.
2016
-
Comparative Effectiveness of Minimally Invasive Hysterectomy for Endometrial Cancer..
34.
2016
-
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone..
34.
2016
-
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database..
34.
2016
-
Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study..
34.
2015
-
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial..
34.
2015
-
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma..
34.
2015
-
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium..
33.
2015
-
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502..
33.
2015
-
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group..
34.
2015
-
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer..
33.
2015
-
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model..
33.
2015
-
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis..
34.
2015
-
Outcomes of Prognostic Disclosure: Associations With Prognostic Understanding, Distress, and Relationship With Physician Among Patients With Advanced Cancer..
33.
2015
-
Psychosocial Outcomes in Adult Survivors of Retinoblastoma..
33.
2015
-
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial..
34.
2015
-
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study..
33.
2015
-
Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk..
33.
2015
-
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed..
33.
2015
-
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline..
33.
2015
-
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial..
33.
2015
-
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility..
33.
2015
-
Racial/Ethnic Differences in Inpatient Palliative Care Consultation for Patients With Advanced Cancer..
33.
2015
-
Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance..
33.
2015
-
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)..
33.
2015
-
Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance)..
33.
2015
-
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors..
33.
2015
-
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center..
33.
2015
-
Intestinal Obstruction in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study..
33.
2015
-
Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival..
33.
2015
-
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project..
33.
2015
-
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study..
33.
2015
-
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study..
33.
2015
-
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108..
33.
2015
-
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens..
33.
2015
-
Mental Health Services for Parents Who Lost a Child to Cancer: If We Build Them, Will They Come?.
33.
2015
-
Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors..
33.
2015
-
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline..
33.
2015
-
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors..
33.
2015
-
Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer..
33.
2015
-
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer..
33.
2015
-
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer..
33.
2015
-
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer..
33.
2015
-
Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial..
33.
2015
-
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial..
33.
2015
-
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study..
33.
2015
-
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial..
33.
2015
-
Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer..
33.
2015
-
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases..
33.
2015
-
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results..
33.
2015
-
RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation..
33.
2015
-
Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology..
33.
2015
-
Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study..
33.
2015
-
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer..
33.
2014
-
Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation..
33.
2014
-
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment..
33.
2014
-
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial..
33.
2014
-
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors..
33.
2014
-
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial..
33.
2014
-
American Society of Clinical Oncology policy statement on medicaid reform..
32.
2014
-
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database..
33.
2014
-
Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance)..
32.
2014
-
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer..
33.
2014
-
Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: a report from the childhood cancer survivor study..
32.
2014
-
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study..
32.
2014
-
Individual prediction of heart failure among childhood cancer survivors..
33.
2014
-
American Society of Clinical Oncology position statement on obesity and cancer..
32.
2014
-
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma..
32.
2014
-
Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide..
32.
2014
-
Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program..
32.
2014
-
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199..
32.
2014
-
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522..
32.
2014
-
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study..
32.
2014
-
Comparison of local recurrence with conventional and intensity-modulated radiation therapy for primary soft-tissue sarcomas of the extremity..
32.
2014
-
Risk of fracture after radical cystectomy and urinary diversion for bladder cancer..
32.
2014
-
Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy..
32.
2014
-
Hematopoietic stem-cell transplantation for advanced systemic mastocytosis..
32.
2014
-
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study..
32.
2014
-
Psychosexual functioning among adult female survivors of childhood cancer: a report from the childhood cancer survivor study..
32.
2014
-
In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma..
32.
2014
-
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma..
32.
2014
-
Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer..
32.
2014
-
Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial..
32.
2014
-
Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer..
32.
2014
-
Long-term central venous catheter use and risk of infection in older adults with cancer..
32.
2014
-
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance)..
32.
2014
-
Cancer-specific outcomes among young adults without health insurance..
32.
2014
-
Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?.
32.
2014
-
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia..
32.
2014
-
Active idiotypic vaccination versus control immunotherapy for follicular lymphoma..
32.
2014
-
Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma..
33.
2014
-
Breast cancer after chest radiation therapy for childhood cancer..
32.
2014
-
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era..
32.
2014
-
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study..
32.
2014
-
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905..
32.
2014
-
Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study..
32.
2014
-
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)..
32.
2014
-
Prospective study of fertility concerns and preservation strategies in young women with breast cancer..
32.
2014
-
Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia..
32.
2014
-
Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group..
32.
2014
-
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer..
32.
2014
-
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial..
32.
2014
-
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials..
32.
2014
-
Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042..
32.
2013
-
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality..
32.
2013
-
Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group..
32.
2013
-
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins..
32.
2013
-
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma..
32.
2013
-
TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia..
32.
2013
-
False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma..
32.
2013
-
Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study..
31.
2013
-
Delivering high-quality and affordable care throughout the cancer care continuum..
31.
2013
-
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab..
31.
2013
-
Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study..
31.
2013
-
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome..
31.
2013
-
Marital status and survival in patients with cancer..
31.
2013
-
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis..
31.
2013
-
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial..
31.
2013
-
Modifiable risk factors and major cardiac events among adult survivors of childhood cancer..
31.
2013
-
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma..
31.
2013
-
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer..
31.
2013
-
Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study..
31.
2013
-
Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology..
31.
2013
-
Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy..
31.
2013
-
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database..
31.
2013
-
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343..
31.
2013
-
Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial..
31.
2013
-
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma..
31.
2013
-
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma..
31.
2013
-
DNA mismatch repair in prostate cancer..
31.
2013
-
Patient-oncologist alliance, psychosocial well-being, and treatment adherence among young adults with advanced cancer..
31.
2013
-
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study..
31.
2013
-
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation..
31.
2013
-
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial..
31.
2013
-
Lack of specificity of plasma concentrations of inhibin B and follicle-stimulating hormone for identification of azoospermic survivors of childhood cancer: a report from the St Jude lifetime cohort study..
31.
2013
-
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial..
31.
2013
-
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer..
31.
2013
-
Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence..
31.
2012
-
Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study..
31.
2012
-
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma..
31.
2012
-
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor..
31.
2012
-
Why is spiritual care infrequent at the end of life? Spiritual care perceptions among patients, nurses, and physicians and the role of training..
31.
2012
-
Randomized controlled trial of a video decision support tool for cardiopulmonary resuscitation decision making in advanced cancer..
31.
2012
-
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial..
31.
2012
-
Absolute risk prediction of second primary thyroid cancer among 5-year survivors of childhood cancer..
31.
2012
-
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047..
31.
2012
-
Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis..
31.
2012
-
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group..
30.
2012
-
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?.
30.
2012
-
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors..
30.
2012
-
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies..
31.
2012
-
Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study..
30.
2012
-
Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation..
30.
2012
-
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission..
30.
2012
-
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes..
30.
2012
-
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer..
30.
2012
-
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101..
30.
2012
-
Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study..
30.
2012
-
Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study..
30.
2012
-
Comparative genomic analysis of primary versus metastatic colorectal carcinomas..
30.
2012
-
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group..
30.
2012
-
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine..
30.
2012
-
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition..
30.
2012
-
Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum..
30.
2012
-
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial..
30.
2012
-
Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms..
30.
2012
-
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial..
30.
2012
-
Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors..
30.
2012
-
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma..
30.
2012
-
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401..
30.
2012
-
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma..
30.
2012
-
Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer..
30.
2012
-
Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer..
30.
2012
-
Long-term follow-up of children treated for high-grade gliomas: children's oncology group L991 final study report..
30.
2012
-
Variation of second cancer risk by family history of retinoblastoma among long-term survivors..
30.
2012
-
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer..
30.
2012
-
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy..
30.
2012
-
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer..
30.
2012
-
Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor..
30.
2011
-
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases..
30.
2011
-
Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study..
30.
2011
-
Predicting survival after curative colectomy for cancer: individualizing colon cancer staging..
29.
2011
-
From node to pathway blockade: lessons learned from targeting mammalian target of rapamycin..
30.
2011
-
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer..
29.
2011
-
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study..
29.
2011
-
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial..
30.
2011
-
Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapy..
29.
2011
-
Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial..
29.
2011
-
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial..
29.
2011
-
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial..
29.
2011
-
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study..
29.
2011
-
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma..
29.
2011
-
High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis..
29.
2011
-
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581..
29.
2011
-
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803..
29.
2011
-
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes..
29.
2011
-
Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group..
29.
2011
-
Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma..
29.
2011
-
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study..
29.
2011
-
Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study..
29.
2011
-
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes..
29.
2011
-
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study..
29.
2011
-
Vitamin D receptor protein expression in tumor tissue and prostate cancer progression..
29.
2011
-
mRNA expression signature of Gleason grade predicts lethal prostate cancer..
29.
2011
-
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database..
29.
2011
-
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors..
29.
2011
-
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy..
29.
2011
-
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations..
29.
2011
-
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas..
29.
2011
-
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer..
29.
2011
-
Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy..
29.
2011
-
Clinical management factors contribute to the decision for contralateral prophylactic mastectomy..
29.
2011
-
Cost implications of the rapid adoption of newer technologies for treating prostate cancer..
29.
2011
-
Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience..
29.
2011
-
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401..
29.
2011
-
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study..
29.
2011
-
Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer..
29.
2011
-
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia..
29.
2011
-
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors..
29.
2011
-
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study..
29.
2011
-
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma..
29.
2010
-
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma..
29.
2010
-
Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer..
29.
2010
-
Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer..
29.
2010
-
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study..
29.
2010
-
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials..
29.
2010
-
Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology..
28.
2010
-
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors..
28.
2010
-
Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve..
28.
2010
-
Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health..
28.
2010
-
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium..
28.
2010
-
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers..
28.
2010
-
Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803..
28.
2010
-
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer..
28.
2010
-
Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer..
28.
2010
-
Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival..
28.
2010
-
Scale to predict survival after surgery for recurrent glioblastoma multiforme..
28.
2010
-
Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ..
28.
2010
-
Randomized clinical trial of telephone-administered cognitive-behavioral therapy to reduce post-traumatic stress disorder and distress symptoms after hematopoietic stem-cell transplantation..
28.
2010
-
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease..
28.
2010
-
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)..
28.
2010
-
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer..
28.
2010
-
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205..
28.
2010
-
Oral bisphosphonate use and breast cancer incidence in postmenopausal women..
28.
2010
-
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer..
28.
2010
-
Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer..
28.
2010
-
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer..
28.
2010
-
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer..
28.
2010
-
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea..
28.
2010
-
Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines..
28.
2010
-
Advanced hepatocellular carcinoma: which staging systems best predict prognosis?.
28.
2010
-
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study..
28.
2010
-
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia..
28.
2010
-
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer..
28.
2010
-
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication..
28.
2010
-
Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial..
28.
2010
-
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases..
28.
2010
-
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2..
28.
2010
-
Patterns and correlates of adjuvant radiotherapy receipt after lumpectomy and after mastectomy for breast cancer..
28.
2010
-
Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas?.
28.
2010
-
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome..
28.
2010
-
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma..
28.
2010
-
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia..
28.
2010
-
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis..
28.
2010
-
Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms..
28.
2010
-
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix..
28.
2010
-
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer..
28.
2010
-
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate..
28.
2010
-
Phase II study of sunitinib in patients with metastatic urothelial cancer..
28.
2010
-
Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial..
28.
2010
-
End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences..
28.
2010
-
Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?.
28.
2010
-
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma..
28.
2010
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial..
28.
2010
-
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era..
28.
2010
-
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection..
28.
2010
-
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer..
28.
2010
-
Provision of spiritual care to patients with advanced cancer: associations with medical care and quality of life near death..
28.
2009
-
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer..
28.
2009
-
Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study..
28.
2009
-
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors..
28.
2009
-
Final version of 2009 AJCC melanoma staging and classification..
27.
2009
-
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction..
27.
2009
-
Nodal staging score: a tool to assess adequate staging of node-negative colon cancer..
27.
2009
-
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone..
28.
2009
-
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer..
28.
2009
-
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma..
27.
2009
-
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial..
27.
2009
-
Racial and ethnic disparities in the use of postmastectomy breast reconstruction: results from a population- based study..
27.
2009
-
Racial differences in predictors of intensive end-of-life care in patients with advanced cancer..
27.
2009
-
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation..
27.
2009
-
Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group..
27.
2009
-
Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors..
27.
2009
-
Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034..
27.
2009
-
Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases..
27.
2009
-
Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer..
27.
2009
-
Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03..
27.
2009
-
Distress in older patients with cancer..
27.
2009
-
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia..
27.
2009
-
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies..
27.
2009
-
Pomalidomide is active in the treatment of anemia associated with myelofibrosis..
27.
2009
-
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium..
27.
2009
-
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma..
27.
2009
-
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era..
27.
2009
-
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial..
27.
2009
-
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy..
27.
2009
-
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy..
27.
2009
-
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma..
27.
2009
-
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial..
27.
2009
-
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment..
27.
2009
-
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma..
27.
2009
-
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma..
27.
2009
-
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer..
27.
2009
-
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results..
27.
2009
-
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas..
27.
2009
-
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?.
27.
2009
-
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma..
27.
2009
-
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy..
27.
2009
-
Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study..
27.
2009
-
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma..
27.
2009
-
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer..
27.
2009
-
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study..
27.
2009
-
Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood..
27.
2009
-
The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy..
27.
2009
-
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer..
27.
2009
-
Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis..
27.
2009
-
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer..
27.
2009
-
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803..
27.
2009
-
Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114)..
27.
2009
-
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases..
27.
2009
-
Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases..
27.
2009
-
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301..
27.
2009
-
Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems..
27.
2009
-
Follicular lymphoma in the United States: first report of the national LymphoCare study..
27.
2009
-
Outcome of deferred initial therapy in mantle-cell lymphoma..
27.
2009
-
Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma..
27.
2009
-
Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival..
27.
2009
-
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma..
27.
2008
-
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology..
27.
2008
-
Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma..
27.
2008
-
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses..
27.
2008
-
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma..
27.
2008
-
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer..
27.
2008
-
Unresolved grief in a national sample of bereaved parents: impaired mental and physical health 4 to 9 years later..
26.
2008
-
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants..
27.
2008
-
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy..
26.
2008
-
Impact of molecular staging methods in primary melanoma: reverse-transcriptase polymerase chain reaction (RT-PCR) of ultrasound-guided aspirate of the sentinel node does not improve diagnostic accuracy, but RT-PCR of peripheral blood does predict survival..
26.
2008
-
Cohort study of fatty acid synthase expression and patient survival in colon cancer..
26.
2008
-
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors..
26.
2008
-
Clinical outcome and predictors of survival in late relapse of germ cell tumor..
26.
2008
-
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402..
26.
2008
-
Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements..
26.
2008
-
Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors..
26.
2008
-
Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study..
26.
2008
-
Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma..
26.
2008
-
Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors..
26.
2008
-
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network..
26.
2008
-
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803..
26.
2008
-
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors..
26.
2008
-
Racial and ethnic differences in advance care planning among patients with cancer: impact of terminal illness acknowledgment, religiousness, and treatment preferences..
26.
2008
-
Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma..
26.
2008
-
Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy..
26.
2008
-
Urgent need for a new staging system in advanced colorectal cancer..
26.
2008
-
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial..
26.
2008
-
Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course..
26.
2008
-
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital..
26.
2008
-
DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors..
26.
2008
-
Effect of esthetic outcome after breast-conserving surgery on psychosocial functioning and quality of life..
26.
2008
-
Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity..
26.
2008
-
Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer..
26.
2008
-
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113..
26.
2008
-
Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study..
26.
2008
-
Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer..
26.
2008
-
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma..
26.
2008
-
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer..
26.
2008
-
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study..
26.
2008
-
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia..
26.
2008
-
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B..
26.
2008
-
Phase II study of extended-dose temozolomide in patients with melanoma..
26.
2008
-
Utilization and outcomes of minimally invasive radical prostatectomy..
26.
2008
-
Potential regional differences for the tolerability profiles of fluoropyrimidines..
26.
2008
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study..
26.
2008
-
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer..
26.
2008
-
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer..
26.
2008
-
Effect of molecular therapeutics on liver regeneration in a murine model..
26.
2008
-
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer..
26.
2008
-
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B..
26.
2008
-
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840..
26.
2008
-
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer..
26.
2008
-
Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy..
26.
2008
-
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy..
26.
2008
-
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib..
26.
2008
-
Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity..
26.
2008
-
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen..
26.
2008
-
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up..
26.
2008
-
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer..
26.
2008
-
Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial..
26.
2008
-
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity..
26.
2008
-
Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population..
26.
2008
-
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103..
26.
2008
-
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study..
26.
2008
-
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer..
26.
2008
-
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group..
26.
2008
-
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group..
26.
2008
-
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer..
26.
2008
-
Individualized prediction of colon cancer recurrence using a nomogram..
26.
2008
-
Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC..
26.
2008
-
Is failure to meet spiritual needs associated with cancer patients' perceptions of quality of care and their satisfaction with care?.
25.
2007
-
Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?.
25.
2007
-
Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer..
25.
2007
-
Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients..
25.
2007
-
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study..
25.
2007
-
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy..
25.
2007
-
Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8..
25.
2007
-
Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299..
25.
2007
-
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption..
25.
2007
-
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16..
26.
2007
-
Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors..
25.
2007
-
Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less..
25.
2007
-
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma..
25.
2007
-
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy..
25.
2007
-
Actual 10-year survival after resection of colorectal liver metastases defines cure..
25.
2007
-
Global histone modifications predict prognosis of resected non small-cell lung cancer..
25.
2007
-
Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection..
25.
2007
-
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study..
25.
2007
-
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma..
25.
2007
-
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer..
25.
2007
-
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer..
25.
2007
-
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience..
25.
2007
-
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803..
25.
2007
-
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab..
25.
2007
-
Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation..
25.
2007
-
Patient satisfaction with treatment of breast cancer: does surgeon specialization matter?.
25.
2007
-
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer..
25.
2007
-
Bevacizumab 5 mg/kg can be infused safely over 10 minutes..
25.
2007
-
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]..
25.
2007
-
Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma..
25.
2007
-
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial..
25.
2007
-
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma..
25.
2007
-
Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group..
25.
2007
-
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy..
25.
2007
-
Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue..
25.
2007
-
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17..
25.
2007
-
Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma..
25.
2007
-
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group..
25.
2007
-
Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma..
25.
2007
-
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy..
25.
2007
-
American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma..
25.
2007
-
Religiousness and spiritual support among advanced cancer patients and associations with end-of-life treatment preferences and quality of life..
25.
2007
-
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors..
25.
2007
-
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis..
25.
2007
-
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years..
25.
2007
-
Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma..
25.
2007
-
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas..
25.
2007
-
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)..
25.
2007
-
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer..
25.
2007
-
Patterns and correlates of patient referral to surgeons for treatment of breast cancer..
25.
2007
-
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors..
25.
2007
-
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer..
25.
2007
-
Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors..
25.
2007
-
Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer..
25.
2007
-
Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study..
24.
2006
-
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology..
25.
2006
-
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia..
25.
2006
-
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia..
25.
2006
-
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma..
24.
2006
-
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma..
24.
2006
-
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model..
24.
2006
-
Molecular on/off switch..
24.
2006
-
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer..
24.
2006
-
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma..
24.
2006
-
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma..
24.
2006
-
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer..
24.
2006
-
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group..
24.
2006
-
Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone..
24.
2006
-
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition..
24.
2006
-
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma..
24.
2006
-
Somatic activation of KIT in distinct subtypes of melanoma..
24.
2006
-
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status..
24.
2006
-
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study..
24.
2006
-
Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer..
24.
2006
-
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803..
24.
2006
-
Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer..
24.
2006
-
Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence..
24.
2006
-
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder..
24.
2006
-
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses..
24.
2006
-
Identifying individuals at high risk of melanoma: a practical predictor of absolute risk..
24.
2006
-
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors..
24.
2006
-
The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members..
24.
2006
-
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor..
24.
2006
-
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia..
24.
2006
-
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients..
24.
2006
-
Translocation carcinomas of the kidney after chemotherapy in childhood..
24.
2006
-
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia..
24.
2006
-
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm..
24.
2006
-
Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome..
24.
2006
-
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors..
24.
2006
-
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)..
24.
2006
-
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas..
24.
2006
-
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study..
24.
2006
-
Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months..
24.
2006
-
Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group..
24.
2006
-
Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma..
24.
2005
-
Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors..
23.
2005
-
Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range..
23.
2005
-
Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183..
23.
2005
-
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma..
24.
2005
-
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies..
24.
2005
-
Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors..
24.
2005
-
Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397)..
23.
2005
-
Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases..
23.
2005
-
Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir..
23.
2005
-
Variates of survival in metastatic uveal melanoma..
23.
2005
-
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline..
23.
2005
-
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study..
23.
2005
-
Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group..
23.
2005
-
Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: results of intergroup protocol ACRIN 6651/GOG 183..
23.
2005
-
Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival..
23.
2005
-
Galectin-1: a link between tumor hypoxia and tumor immune privilege..
23.
2005
-
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials..
23.
2005
-
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab..
23.
2005
-
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy..
23.
2005
-
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial..
23.
2005
-
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)..
23.
2005
-
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy..
23.
2005
-
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada..
23.
2005
-
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas..
23.
2005
-
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors..
23.
2005
-
Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study..
23.
2005
-
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure..
23.
2005
-
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck..
23.
2005
-
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer..
23.
2005
-
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle..
23.
2005
-
Survival in patients operated on for pathologic fracture: implications for end-of-life orthopedic care..
23.
2005
-
Psychiatric disorders and mental health service use among caregivers of advanced cancer patients..
23.
2005
-
Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy..
23.
2005
-
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma..
23.
2005
-
Patient involvement in surgery treatment decisions for breast cancer..
23.
2005
-
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks..
23.
2005
-
Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection?.
23.
2005
-
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer..
23.
2005
-
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research..
23.
2005
-
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome..
23.
2005
-
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer..
23.
2005
-
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study..
23.
2005
-
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients..
23.
2005
-
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma..
23.
2005
-
Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy..
23.
2005
-
Achieving optimal outcomes after radical prostatectomy..
23.
2005
-
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia..
23.
2005
-
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma..
23.
2005
-
Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors..
23.
2005
-
Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy..
23.
2005
-
Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point..
23.
2005
-
Patient online self-reporting of toxicity symptoms during chemotherapy..
23.
2005
-
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer..
23.
2005
-
Patterns and correlates of local therapy for women with ductal carcinoma-in-situ..
23.
2005
-
Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome..
23.
2005
-
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma..
23.
2005
-
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer..
23.
2005
-
Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation..
23.
2005
-
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas..
23.
2005
-
Merkel cell carcinoma: prognosis and treatment of patients from a single institution..
23.
2005
-
Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up..
23.
2005
-
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate..
23.
2005
-
Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy..
23.
2005
-
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13..
23.
2005
-
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer..
23.
2005
-
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer..
23.
2005
-
TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study..
23.
2005
-
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer..
23.
2005
-
ACCO: ASCO core curriculum outline..
23.
2005
-
Molecular staging in stage II and III melanoma patients and its effect on long-term survival..
23.
2005
-
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial..
23.
2005
-
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors..
23.
2005
-
Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer..
23.
2005
-
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry..
23.
2005
-
Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse..
23.
2005
-
Prognostic implications of multiple lymphatic basin drainage in patients with truncal melanoma..
23.
2005
-
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes..
23.
2005
-
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma..
23.
2004
-
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma..
22.
2004
-
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team..
23.
2004
-
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer..
22.
2004
-
Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344..
23.
2004
-
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma..
22.
2004
-
Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck..
22.
2004
-
Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction--staged sentinel lymph nodes from melanoma patients..
22.
2004
-
Phase II trial of bortezomib for patients with advanced renal cell carcinoma..
22.
2004
-
Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study..
22.
2004
-
Use of surgery among elderly patients with stage IV colorectal cancer..
22.
2004
-
Early detection and prognosis of ovarian cancer using serum YKL-40..
22.
2004
-
Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors..
22.
2004
-
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor..
22.
2004
-
Using health-related quality of life measures to predict cardiac function in survivors exposed to anthracyclines..
22.
2004
-
Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study..
22.
2004
-
Cost minimization study of image-guided core biopsy versus surgical excisional biopsy for women with abnormal mammograms..
22.
2004
-
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation..
22.
2004
-
Surgical factors influence bladder cancer outcomes: a cooperative group report..
22.
2004
-
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342..
22.
2004
-
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer..
22.
2004
-
Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors..
22.
2004
-
Acupuncture for postchemotherapy fatigue: a phase II study..
22.
2004
-
Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy..
22.
2004
-
Using patients as their own controls for cost evaluation of phase I clinical trials..
22.
2004
-
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer..
22.
2004
-
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan..
22.
2004
-
Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines..
22.
2004
-
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1..
22.
2004
-
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2..
22.
2004
-
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients..
22.
2004
-
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor..
22.
2004
-
Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol..
22.
2004
-
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma..
22.
2004
-
p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer..
22.
2004
-
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma..
22.
2004
-
Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy..
22.
2004
-
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications..
22.
2004
-
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck..
22.
2004
-
Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy..
22.
2004
-
Interaction of splenectomy and perioperative blood transfusions on prognosis of patients with proximal gastric and gastroesophageal junction cancer..
21.
2003
-
Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer..
21.
2003
-
Chemotherapy for teratoma with malignant transformation..
21.
2003
-
Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine..
21.
2003
-
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor..
21.
2003
-
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis..
21.
2003
-
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia..
21.
2003
-
Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02..
21.
2003
-
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975..
21.
2003
-
Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma..
21.
2003
-
Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma..
21.
2003
-
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults..
21.
2003
-
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation..
21.
2003
-
Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study..
21.
2003
-
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer..
21.
2003
-
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma..
21.
2003
-
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma..
21.
2003
-
Automated, multiplex assay for high-frequency microsatellite instability in colorectal cancer..
21.
2003
-
Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma..
21.
2003
-
The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer..
21.
2003
-
Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer..
21.
2003
-
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer..
21.
2003
-
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer..
21.
2003
-
Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor..
21.
2003
-
Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time..
21.
2003
-
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study..
21.
2003
-
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma..
21.
2003
-
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study..
21.
2003
-
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas..
21.
2003
-
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer..
21.
2003
-
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study..
21.
2003
-
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]..
21.
2003
-
Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling..
21.
2003
-
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B..
21.
2003
-
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140..
21.
2003
-
Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes..
21.
2003
-
Resistance exercise in men receiving androgen deprivation therapy for prostate cancer..
21.
2003
-
Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study..
21.
2003
-
Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein..
21.
2003
-
Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study..
21.
2003
-
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia..
21.
2003
-
Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy..
21.
2003
-
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer..
21.
2003
-
Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma..
21.
2003
-
Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial..
21.
2003
-
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741..
21.
2003
-
Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer..
21.
2003
-
Role of surgeon volume in radical prostatectomy outcomes..
21.
2003
-
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer..
21.
2003
-
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial..
21.
2003
-
Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma..
21.
2003
-
Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors..
20.
2002
-
Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10..
20.
2002
-
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer..
20.
2002
-
Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables..
20.
2002
-
Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma..
20.
2002
-
Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer..
20.
2002
-
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration..
20.
2002
-
Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923..
20.
2002
-
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology..
20.
2002
-
Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors..
20.
2002
-
Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: results from a randomized trial..
20.
2002
-
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer..
20.
2002
-
Revision of the American Joint Committee on Cancer staging system for breast cancer..
20.
2002
-
Complication rates among cancer patients with peripherally inserted central catheters..
20.
2002
-
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy..
20.
2002
-
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder..
20.
2002
-
Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent..
20.
2002
-
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial..
20.
2002
-
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups..
20.
2002
-
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial..
20.
2002
-
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer..
20.
2002
-
Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire..
20.
2002
-
Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors..
20.
2002
-
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology..
20.
2002
-
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial..
20.
2002
-
Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?.
20.
2002
-
Long-term results of combined-modality therapy in resectable non-small-cell lung cancer..
20.
2002
-
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors..
20.
2002
-
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer..
20.
2002
-
Safe and cost effective use of alteplase for the clearance of occluded central venous access devices..
20.
2002
-
Adjuvant radiation for stage II-B soft tissue sarcoma of the extremity..
20.
2002
-
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors..
20.
2002
-
Cardiac dysfunction in the trastuzumab clinical trials experience..
20.
2002
-
Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma..
20.
2002
-
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy..
20.
2002
-
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers..
20.
2002
-
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer..
20.
2002
-
Adrenocortical carcinoma: clinical, morphologic, and molecular characterization..
20.
2002
-
Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer..
20.
2002
-
Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869..
20.
2002
-
Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis..
20.
2002
-
Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer?.
20.
2002
-
High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry..
20.
2002
-
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up..
20.
2002
-
Postoperative nomogram for 12-year sarcoma-specific death..
20.
2002
-
Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma..
20.
2002
-
Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation..
20.
2002
-
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma..
20.
2002
-
Phase II trial of thalidomide for patients with advanced renal cell carcinoma..
20.
2002
-
Salvage chemotherapy for patients with advanced pure seminoma..
20.
2002
-
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies..
20.
2002
-
Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma..
19.
2001
-
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas..
19.
2001
-
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia..
19.
2001
-
Impact of high-dose chemotherapy on peripheral T-cell lymphomas..
19.
2001
-
Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare..
19.
2001
-
Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction..
19.
2001
-
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system..
19.
2001
-
Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors..
19.
2001
-
Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients..
19.
2001
-
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies..
19.
2001
-
High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis..
19.
2001
-
Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery..
19.
2001
-
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties..
19.
2001
-
Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy..
19.
2001
-
Hürthle cell carcinoma: a critical histopathologic appraisal..
19.
2001
-
Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer..
19.
2001
-
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924..
19.
2001
-
Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer..
19.
2001
-
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification..
19.
2001
-
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results..
19.
2001
-
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel..
19.
2001
-
Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy..
19.
2001
-
Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma..
19.
2001
-
Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy..
19.
2001
-
Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies..
19.
2001
-
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse..
19.
2001
-
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer..
19.
2001
-
Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma..
19.
2001
-
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696..
19.
2001
-
Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma..
19.
2001
-
Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma..
19.
2001
-
Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy..
19.
2001
-
Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion..
19.
2001
-
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients..
19.
2001
-
Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum..
19.
2001
-
Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry..
19.
2001
-
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer..
19.
2001
-
Transurethral resection of muscle-invasive bladder cancer: 10-year outcome..
19.
2001
-
Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance..
19.
2001
-
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies..
18.
2000
-
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer..
18.
2000
-
Abnormalities of chromosome bands 13q12 to 13q14 in childhood acute lymphoblastic leukemia..
18.
2000
-
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer..
18.
2000
-
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer..
18.
2000
-
Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer..
18.
2000
-
Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group..
18.
2000
-
Treatment for primary CNS lymphoma: the next step..
18.
2000
-
Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma..
18.
2000
-
Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)..
18.
2000
-
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide..
18.
2000
-
MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study..
18.
2000
-
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors..
18.
2000
-
Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point..
18.
2000
-
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer..
18.
2000
-
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group..
18.
2000
-
Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia..
18.
2000
-
Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma..
18.
2000
-
Evaluation of tumor measurements in oncology: use of film-based and electronic techniques..
18.
2000
-
Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes)..
18.
2000
-
Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer..
18.
2000
-
Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial..
18.
2000
-
Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity..
18.
2000
-
Influence of biologic factors and anatomic site in completely resected liposarcoma..
18.
2000
-
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas..
18.
2000
-
Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer..
18.
2000
-
Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy..
18.
2000
-
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013..
18.
2000
-
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients..
18.
2000
-
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract..
18.
2000
-
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin..
18.
2000
-
Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus..
18.
2000
-
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas..
18.
2000
-
Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia..
18.
2000
-
New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia..
18.
2000
-
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies..
18.
2000
-
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies..
18.
2000
-
Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia..
17.
1999
-
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma..
17.
1999
-
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group..
17.
1999
-
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer..
17.
1999
-
Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk..
17.
1999
-
Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy..
17.
1999
-
Oral etoposide for refractory and relapsed neuroblastoma..
17.
1999
-
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer..
17.
1999
-
Expression of HER2/erbB-2 correlates with survival in osteosarcoma..
17.
1999
-
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma..
17.
1999
-
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma..
17.
1999
-
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma..
17.
1999
-
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer..
17.
1999
-
Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group Study 8821..
17.
1999
-
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer..
17.
1999
-
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642..
17.
1999
-
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study..
17.
1999
-
Outcome for cancer patients requiring mechanical ventilation..
17.
1999
-
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer..
17.
1999
-
Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry..
17.
1999
-
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy..
17.
1999
-
Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer..
17.
1999
-
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome..
17.
1999
-
Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer..
17.
1999
-
Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group..
17.
1999
-
Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study..
17.
1999
-
Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741..
17.
1999
-
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy..
17.
1999
-
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine..
17.
1999
-
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma..
16.
1998
-
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors..
16.
1998
-
Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy..
16.
1998
-
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group..
16.
1998
-
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age..
16.
1998
-
Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants..
16.
1998
-
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors..
16.
1998
-
Postmastectomy radiotherapy: questions for the twenty-first century..
16.
1998
-
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies..
16.
1998
-
Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial..
16.
1998
-
Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol..
16.
1998
-
Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors..
16.
1998
-
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk..
16.
1998
-
Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis..
16.
1998
-
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group..
16.
1998
-
Resection of metastatic renal cell carcinoma..
16.
1998
-
Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis..
16.
1998
-
BRCA-associated breast cancer in young women..
16.
1998
-
Diagnosis in oncology. Askin tumor..
16.
1998
-
Emerging role of laparoscopy in the diagnosis of lymphoma..
16.
1998
-
High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma..
16.
1998
-
Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer..
16.
1998
-
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus..
16.
1998
-
Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B..
16.
1998
-
Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone..
16.
1998
-
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma..
16.
1998
-
Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group..
16.
1998
-
Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma..
16.
1998
-
Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome..
16.
1998
-
Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer..
16.
1998
-
Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease..
16.
1998
-
Extravesical tumor relapse in patients with superficial bladder tumors..
16.
1998
-
Long-term survival in primary CNS lymphoma..
16.
1998
-
Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center..
16.
1998
-
Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group..
16.
1998
-
Metastatic germ cell tumors: modeling for response to chemotherapy..
16.
1998
-
Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model..
16.
1998
-
Paternity in men with stage I testis tumors on surveillance..
16.
1998
-
High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group..
16.
1998
-
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome..
16.
1998
-
Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors..
16.
1998
-
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer..
16.
1998
-
Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies..
15.
1997
-
Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer..
15.
1997
-
Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer..
15.
1997
-
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease..
15.
1997
-
Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive?.
15.
1997
-
Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management..
15.
1997
-
Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study..
15.
1997
-
High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors..
15.
1997
-
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival..
15.
1997
-
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin..
15.
1997
-
Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study..
15.
1997
-
Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults..
15.
1997
-
Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma..
15.
1997
-
Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer..
15.
1997
-
Endoscopic ultrasound in the evaluation of gastric small lymphocytic mucosa-associated lymphoid tumors..
15.
1997
-
Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma..
15.
1997
-
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma..
15.
1997
-
Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone..
15.
1997
-
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group..
15.
1997
-
Fatty acid composition of adipose tissue, an indication of dietary fatty acids, and breast cancer prognosis..
15.
1997
-
Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer..
15.
1997
-
Liver resection for colorectal metastases..
15.
1997
-
Association of local recurrence with subsequent survival in extremity soft tissue sarcoma..
15.
1997
-
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069..
15.
1997
-
Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue..
15.
1997
-
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre..
15.
1997
-
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer..
15.
1997
-
Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia..
15.
1997
-
Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study..
15.
1997
-
Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study..
14.
1996
-
Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies..
14.
1996
-
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors..
14.
1996
-
Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome..
14.
1996
-
p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases..
14.
1996
-
Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone..
14.
1996
-
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group..
14.
1996
-
Carboxypeptidase G2 rescue after high-dose methotrexate..
14.
1996
-
Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy..
14.
1996
-
Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil..
14.
1996
-
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer..
14.
1996
-
Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics..
14.
1996
-
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer..
14.
1996
-
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis..
14.
1996
-
Tobacco control: reducing cancer incidence and saving lives. American Society of Clinical Oncology..
14.
1996
-
Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities..
14.
1996
-
Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy..
14.
1996
-
Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer..
14.
1996
-
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study..
14.
1996
-
Psychologic and neuropsychologic impact of autologous bone marrow transplantation..
14.
1996
-
Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease..
14.
1996
-
High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity..
14.
1996
-
Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival..
14.
1996
-
Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide..
14.
1996
-
Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group..
14.
1996
-
Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast..
14.
1996
-
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer..
14.
1996
-
Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma..
14.
1996
-
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer..
14.
1996
-
Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group..
14.
1996
-
Funding for clinical (patient-oriented) oncology research: current status and recommendations for improvement. American Society of Clinical Oncology..
14.
1996
-
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center..
14.
1996
-
Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: implications for management..
14.
1996
-
Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy..
14.
1996
-
Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122..
14.
1996
-
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer..
14.
1996
-
Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group..
14.
1996
-
Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control?.
13.
1995
-
Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors..
13.
1995
-
Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults..
13.
1995
-
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer..
13.
1995
-
Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer..
13.
1995
-
Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer..
13.
1995
-
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen..
13.
1995
-
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805..
13.
1995
-
Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro..
13.
1995
-
Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma..
13.
1995
-
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience..
13.
1995
-
Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281..
13.
1995
-
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study..
13.
1995
-
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial..
13.
1995
-
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC..
13.
1995
-
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management..
13.
1995
-
Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications..
13.
1995
-
Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses..
13.
1995
-
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response..
13.
1995
-
Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups..
13.
1995
-
p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis..
13.
1995
-
Organ-function preservation in advanced oropharynx cancer: results with induction chemotherapy and radiation..
13.
1995
-
Pain and depression in patients with newly diagnosed pancreas cancer..
13.
1995
-
Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group..
13.
1995
-
Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer..
13.
1995
-
Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy..
13.
1995
-
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site..
13.
1995
-
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial..
13.
1995
-
Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age..
12.
1994
-
Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer..
12.
1994
-
Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma..
12.
1994
-
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors..
12.
1994
-
Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies..
12.
1994
-
Pharmacologic-guided trial of sequential methotrexate and thioguanine in children with advanced malignancies..
12.
1994
-
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer..
12.
1994
-
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up..
12.
1994
-
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma..
12.
1994
-
A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk..
12.
1994
-
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts..
12.
1994
-
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer..
12.
1994
-
Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin..
12.
1994
-
Effects of topical tretinoin on dysplastic nevi..
12.
1994
-
Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer..
12.
1994
-
Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results..
12.
1994
-
Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil..
12.
1994
-
Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma..
12.
1994
-
Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients..
12.
1994
-
Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group..
12.
1994
-
Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy..
12.
1994
-
Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study..
11.
1993
-
Preoperative endoscopic ultrasound can predict the risk of recurrence after operation for gastric carcinoma..
11.
1993
-
Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B..
11.
1993
-
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up..
11.
1993
-
Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106..
11.
1993
-
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer..
11.
1993
-
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma..
11.
1993
-
Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials..
11.
1993
-
Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma..
11.
1993
-
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer..
11.
1993
-
Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up..
11.
1993
-
Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group..
11.
1993
-
Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease..
11.
1993
-
Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia..
11.
1993
-
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer..
11.
1993
-
Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer..
11.
1993
-
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250..
11.
1993
-
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer..
11.
1993
-
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study..
11.
1993
-
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer..
11.
1993
-
Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC..
11.
1993
-
Osteogenic sarcoma with clinically detectable metastasis at initial presentation..
11.
1993
-
Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer..
11.
1993
-
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias..
11.
1993
-
Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer..
11.
1993
-
Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients..
10.
1992
-
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer..
10.
1992
-
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study..
10.
1992
-
Radiosurgery as part of the initial management of patients with malignant gliomas..
10.
1992
-
Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach..
10.
1992
-
Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults..
10.
1992
-
A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma..
10.
1992
-
Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies..
10.
1992
-
Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation..
10.
1992
-
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer..
10.
1992
-
Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group..
10.
1992
-
Combined modality therapy for primary CNS lymphoma..
10.
1992
-
FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer..
10.
1992
-
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease..
10.
1992
-
Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer..
10.
1992
-
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience..
10.
1992
-
Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy..
10.
1992
-
Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies..
10.
1992
-
A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study..
9.
1991
-
Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations..
9.
1991
-
The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B..
9.
1991
-
Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin..
9.
1991
-
A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia..
9.
1991
-
Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma..
9.
1991
-
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study..
9.
1991
-
A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms..
9.
1991
-
Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer..
9.
1991
-
The prognosis of Hodgkin's disease in older adults..
9.
1991
-
A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide..
9.
1991
-
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin..
9.
1991
-
Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma..
9.
1991
-
Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial..
9.
1991
-
Myeloablative combination chemotherapy without total body irradiation for neuroblastoma..
9.
1991
-
Cardiopulmonary resuscitation and the patient with cancer..
9.
1991
-
Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group..
8.
1990
-
Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma..
8.
1990
-
Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33..
8.
1990
-
Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease..
8.
1990
-
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection..
8.
1990
-
Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy..
8.
1990
-
A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression..
8.
1990
-
The treatment of recurrent brain metastases with stereotactic radiosurgery..
8.
1990
-
Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma..
8.
1990
-
Prognostic factors for positive surgical staging in patients with Hodgkin's disease..
8.
1990
-
Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer..
8.
1990
-
High-dose ifosfamide with mesna uroprotection: a phase I study..
8.
1990
-
Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer..
8.
1990
-
The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen..
8.
1990
-
Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas..
8.
1990
-
A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2..
7.
1989
-
Inability of computed tomography appearance of recurrent malignant astrocytoma to predict survival following reoperation..
7.
1989
-
Spondylectomy for malignant tumors of the spine..
7.
1989
-
Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma..
7.
1989
-
Flow cytometry as a predictive indicator in patients with operable gastric cancer..
7.
1989
-
Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation..
7.
1989
-
Should single agents be standard therapy for urothelial tract tumors?.
7.
1989
-
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support..
7.
1989
-
Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy..
7.
1989
-
Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer..
7.
1989
-
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma..
7.
1989
-
Cardiorespiratory effects of immunotherapy with interleukin-2..
7.
1989
-
Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin..
7.
1989
-
Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer..
6.
1988
-
The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia..
6.
1988
-
A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors..
6.
1988
-
Autologous bone marrow transplantation for patients with poor-prognosis lymphoma..
6.
1988
-
Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy..
6.
1988
-
A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969..
6.
1988
-
Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies..
6.
1988
-
Control of chemotherapy-induced diarrhea with the synthetic enkephalin BW942C: a randomized trial with placebo in patients receiving cisplatin..
6.
1988
-
Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy..
6.
1988
-
Chemotherapeutic and surgical induction of pathological complete remission and whole abdominal irradiation for consolidation does not enhance the cure of stage III ovarian carcinoma..
6.
1988
-
High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for CNS leukemia..
6.
1988
-
Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer..
6.
1988
-
Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer..
6.
1988
-
A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen..
5.
1987
-
Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer..
5.
1987
-
Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: experience with 100 patients..
5.
1987
-
Tumor and liver drug uptake following hepatic artery and portal vein infusion..
5.
1987
-
Phase I trial of escalating doses of cisplatin in hypertonic saline..
5.
1987
-
Very-high-dose cisplatin with bleomycin infusion as initial treatment of advanced head and neck cancer..
5.
1987
-
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma..
5.
1987
-
Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy..
5.
1987
-
Eligibility and extrapolation in cancer clinical trials..
5.
1987
-
Localized extremity soft tissue sarcoma: an analysis of factors affecting survival..
5.
1987
-
A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer..
5.
1987
-
Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors..
5.
1987
-
Wound complications in the multimodality treatment of extremity and superficial truncal sarcomas..
5.
1987
-
A phase I-II study of intensive-dose adriamycin for advanced breast cancer..
5.
1987
-
Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases..
5.
1987
-
Semen cryopreservation and artificial insemination for Hodgkin's disease..
5.
1987
-
Surgical treatment of spinal cord compression in kidney cancer..
4.
1986
-
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy..
4.
1986
-
Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors..
4.
1986
-
Gonadal dysfunction in patients treated for metastatic germ-cell tumors..
4.
1986
-
VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors..
4.
1986
-
Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group..
4.
1986
-
Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia..
4.
1986
-
Medical oncology manpower training: a position statement of the American Society of Clinical Oncology..
4.
1986
-
Phase I trial of recombinant interferon gamma in cancer patients..
4.
1986
-
Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity..
4.
1986
-
Improvements in data collection through physician use of a computer-based chemotherapy treatment consultant..
3.
1985
-
Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin..
3.
1985
-
Therapy of CNS leukemia with intraventricular chemotherapy and low-dose neuraxis radiotherapy..
3.
1985
-
The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era: the Memorial Sloan-Kettering Cancer Center experience (1975 to 1982)..
3.
1985
-
The significance of the residual mediastinal mass in treated Hodgkin's disease..
3.
1985
-
13-cis-Retinoic acid does not increase the true remission rate and the duration of true remission (induced by cytotoxic chemotherapy) in patients with chronic phase chronic myelogenous leukemia..
3.
1985
-
VAB-6 as initial treatment of patients with advanced seminoma..
3.
1985
-
Chronic myelogenous leukemia: is aggressive treatment indicated?.
3.
1985
-
Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate..
3.
1985
-
Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly..
2.
1984
-
The treatment of extragonadal seminoma..
2.
1984
-
Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma..
2.
1984
-
A critical comparison of allogeneic bone marrow transplantation and conventional chemotherapy as treatment for acute nonlymphocytic leukemia..
2.
1984
-
Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate..
2.
1984
-
Orchiectomy alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis..
2.
1984
-
Philadelphia chromosome and terminal transferase-positive acute leukemia: similarity of terminal phase of chronic myelogenous leukemia and de novo acute presentation..
1.
1983
-
Marrow cytogenetic and cell-culture analyses of the myelodysplastic syndromes: insights to pathophysiology and prognosis..
1.
1983
-
A technique to quantify cytoreduction in the bone marrow induced by cytotoxic chemotherapy..
1.
1983
-
Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: a Cancer and Leukemia Group B study..
1.
1983
-
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial..
41.
2023
-
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer..
41.
2023
-
Reply to F. Tomao et al..
37.
2019
-
Reply to C. Ren et al..
36.
2018
-
Understanding Responses to Stereotactic Body Radiotherapy and Pembrolizumab..
36.
2018
-
Stereotactic Body Radiation Therapy: Focusing on the Short Game..
36.
2018
-
Learning All That We Can From MyPathway..
36.
2018
-
Reply to K.S. Shohdy et al..
36.
2018
-
Reply to E. Younger et al..
36.
2018
-
Exercise Implementation in Oncology: One Size Does Not Fit All..
36.
2018
-
Reply to M. Horiguchi et al..
36.
2018
-
Reply to M. Mo et al..
36.
2017
-
Reply to D.J. Beale..
35.
2017
-
Reply to C.G. Rusthoven et al..
35.
2017
-
Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia..
35.
2017
-
Reply to R.L. Nussbaum et al and J.S. Dolinsky et al..
35.
2017
-
Reply to L.B. Marks et al..
35.
2017
-
Reply to K. Kusaka et al..
35.
2017
-
Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment..
35.
2016
-
It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma..
35.
2016
-
Reply to M. Nishino..
34.
2016
-
Reply to J. Jupp et al..
34.
2016
-
Not All Androgen Deprivation Therapies Are Created Equal: Leuprolide and the Decreased Risk of Developing Alzheimer's Disease..
34.
2016
-
Reply to N. Lowy et al and to J. Dhanda et al..
34.
2016
-
Reply to O.O. Eren et al and S. Mikhail..
34.
2016
-
Genetic Screening in All Young Patients With Colorectal Cancer?.
34.
2016
-
Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era..
34.
2016
-
Parsing the Etiology of Breast Cancer Disparities..
34.
2016
-
Reply to A. Indini et al..
34.
2016
-
Reply to M.P. Decatris et al..
34.
2016
-
Reply to A. Addeo and A. Bahl..
34.
2015
-
Reply to S.M. Sorscher and A.B. Hafeez Bhatti..
33.
2015
-
Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al..
33.
2015
-
There Is Nothing New Under the Sun..
33.
2015
-
Reply to K. Lu..
33.
2015
-
Reply to D. Spiegel..
33.
2015
-
Reply to A. Stenzinger et al..
33.
2015
-
Reply to B. O'Sullivan et Al..
33.
2015
-
Reply to D. Adkins et al..
33.
2015
-
Reply to P. Stattin..
33.
2015
-
National Cancer Institute-supported clinical trials networks..
33.
2014
-
When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?.
32.
2014
-
Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases..
32.
2014
-
Reply to M. Voskoboynik et al..
32.
2014
-
Minimal residual disease: what are the minimum requirements?.
32.
2014
-
Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al..
31.
2013
-
Role of expression profiling in carcinoma of unknown primary remains unknown..
31.
2013
-
Reply to L. Moreno et al..
31.
2013
-
Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer?.
31.
2012
-
Response to crizotinib in ROS1-rearranged non-small-cell lung cancer..
30.
2012
-
Risk factors for the incidence of second cancers in survivors of retinoblastoma with a family history..
30.
2012
-
HER2 mutations in non-small-cell lung cancer can be continually targeted..
30.
2012
-
Neoadjuvant chemotherapy is rarely the easy way out..
30.
2012
-
Targeting vascular endothelial growth factor in patients with squamous cell lung cancer..
30.
2012
-
Misunderstanding regarding the carboplatin dose comparison in MRC TE19/EORTC 30982..
29.
2011
-
Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting..
29.
2011
-
Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms..
29.
2011
-
Osteonecrosis of the jaw after zoledronic acid and denosumab treatment..
29.
2011
-
Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results?.
29.
2011
-
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?.
29.
2011
-
Thymoma-associated paraneoplastic polymyositis..
28.
2010
-
Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma..
28.
2010
-
Neurocutaneous melanocytosis: outcome not uniformly fatal..
27.
2009
-
Effects of chemoradiation on tumor-host interactions: the immunologic side..
26.
2008
-
Isn't there someone to blame?.
26.
2008
-
Bevacizumab: one treatment for all the seasons?.
26.
2008
-
End points in advanced colon cancer clinical trials: a review and proposal..
25.
2007
-
Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan..
25.
2007
-
New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor..
24.
2006
-
Medullary renal cell carcinoma and response to therapy with bortezomib..
24.
2006
-
Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy..
23.
2005
-
Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy?.
23.
2005
-
Operate on my stomach cancer? Oh, no--not you, or not yet!.
22.
2004
-
Ototoxicity in patients with dose-intensive therapy for cisplatin-resistant germ cell tumors..
22.
2004
-
TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies..
22.
2004
-
Fludarabine-related myeloid leukemia..
21.
2003
-
Cardiac dysfunction in clinical trials of trastuzumab..
20.
2002
-
Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope..
20.
2002
-
Endothelial dysfunction in antiangiogenesis-associated thrombosis..
20.
2002
-
Role of symptom control and palliative care abstract presentations..
20.
2002
-
Utilization of breast-conserving surgery in breast cancer..
19.
2001
-
Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor..
19.
2001
-
Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: intergroup 116..
19.
2001
-
Re: "Bezwoda: evidence of fabrication in original article"..
18.
2000
-
Bezwoda: evidence of fabrication in original article..
18.
2000
-
Dexrazoxane in anthracycline extravasation..
18.
2000
-
Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique..
18.
2000
-
Predictors of response to chemotherapy..
18.
2000
-
BRCA1/2 germline mutations: a marker for radioresistance or radiosensitivity?.
18.
2000
-
Gemcitabine is active in relapsed Hodgkin's disease..
17.
1999
-
Institutional review board review of research reported in the journal of clinical oncology..
17.
1999
-
Should we delay prostate radiotherapy?.
17.
1999
-
Chemotherapy of advanced non-small-cell lung cancer: "Those who cannot remember the past are condemned to repeat it"..
17.
1999
-
Radiotherapy with/without cisplatin following chemotherapy in limited small-cell lung cancer..
16.
1998
-
BRCA mutations and survival in breast cancer..
16.
1998
-
Monitoring methotrexate levels in osteosarcoma..
16.
1998
-
Don't be mis-guided when the data are silent and the editorial misses the mark..
16.
1998
-
Bleomycin in nonseminomatous germ-cell tumors: cure rate versus morbidity..
16.
1998
-
Delayed complication of Port-A-Cath: perforation of the superior vena cava..
15.
1997
-
Do all germ cell tumor patients with residual masses in multiple sites require postchemotherapy resections?.
15.
1997
-
Optimal management of residual mass after chemotherapy in advanced seminoma: there is time for everything..
14.
1996
-
Cytoreduction and prognosis in childhood acute lymphoblastic leukemia..
14.
1996
-
Adjuvant chemotherapy in pathologic Stage II nonseminomatous testicular cancer: are two cycles of etoposide-cisplatin a standard option?.
14.
1996
-
Defining new standards for adjuvant therapy of testis cancer: a reply..
14.
1996
-
Chemotherapy for colorectal carcinoma: observations regarding recent clinical trials using biochemical modulation..
13.
1995
-
Calvert's formula and high-dose carboplatin..
12.
1994
-
Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2..
12.
1994
-
Combination chemotherapy for metastatic melanoma: the importance of tamoxifen..
12.
1994
-
Rethinking management of localized neuroblastoma..
11.
1993
-
Use of stereotactic radiosurgery in the treatment of malignant glioma..
11.
1993
-
Phase II trials of small-cell lung cancer..
10.
1992
-
Reassessment of patient response to monoclonal antibody 3F8..
10.
1992
-
Neoadjuvant chemotherapy in head and neck cancer: no way to preserve a larynx..
10.
1992
-
Dose-intensity analysis and randomized trials..
9.
1991
-
Cyclophosphamide and the heart..
9.
1991
-
Pseudo-Philadelphia-positive acute lymphoblastic leukemia (Ph1 + ALL).
5.
1987
-
Philadelphia chromosome mosaicism in chronic granulocytic leukemia..
4.
1986
-
Patients with secondary acute myelocytic leukemia (AML) receiving "timed" sequential chemotherapy..
1.
1983
-
Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors.
2022
-
Reply to T.M. Weis et al.
2019
-
Targeting DNA Repair in Prostate Cancer.
2018
-
Reply to T. Olivier et al.
2022
-
Reply to K. de Joode et al.
2021
-
Considerations for the Use of Scalp Cooling Devices in Black Patients.
2020
-
Reply to N. Fazio.
2020
-
Reply to A. Katz.
2019
-
Reply to E. Hindié et al.
2019
-
Reply to H. Brauch et al.
2019
-
Reply to I. Pecora et al.
2019
-
Reply to J.L. Blum et al and S. Lange et al.
2017
-
Population Frequency of Germline BRCA1/2 Mutations.
2016
-
Reply to G. Le Flahec et al.
2016
-
Reply to A. Braillon, M. Boulin et al, and J.-H. Zhong et al.
2016
-
Reply to T. Finazzi and H. Kim et al.
2016
-
Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.
2014
-
Reply to S. Barni et Al and M. Sun et Al.
2014
-
Reply to K.I. Pritchard.
2013
-
Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice?
2012
-
Febrile neutropenia and infection in the ASCENT studies.
2011
-
T-cell-depleted reduced-intensity conditioning transplantation for lymphoma: do donor lymphocyte infusions really matter?
2011
-
Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism?
2010
-
African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.
2009
-
Impact of immediate postoperative death on the estimation of a survival benefit from postoperative radiation therapy for cancer of the gallbladder.
2008
-
Risk of ipsilateral lung cancer after postmastectomy radiotherapy and smoking: does the possible triumph over the actual?
2008
-
Superiority of reduced-intensity conditioning for Hodgkin's lymphoma.
2008
-
Circulating tumor cells in breast cancer: fiction or reality?
2008
-
Dose-dense chemotherapy with trastuzumab is an appropriate option.
2008
-
Hepatic arterial infusion chemotherapy for metastases from colorectal cancer: is it really the end of an era?
2008
-
Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support.
2006
-
Lipophilic statins merit additional study for breast cancer chemoprevention.
2006
-
Inflammatory breast cancer and high-dose chemotherapy: back to the past.
2005
-
Inflammatory breast carcinoma: the sphinx of breast cancer research.
2004
-
Benefit of Paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer.
2003
-
Conformal radiotherapy for high-grade gliomas: how much is too much?
2002
-
Classifying chronic myelomonocytic leukemia.
2001
-
Allogeneic transplantation for low-grade lymphoma: long-term follow-up.
2000
-
Prognostic factors in bladder cancer after primary M-VAC.
1995
-
Timing of radiotherapy in the treatment of early-stage breast cancer.
1993
-
Amsacrine retains a special role supporting Food and Drug Administration approval.
1992
-
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.
2009
-
Cognitive impairment associated with chemotherapy for cancer: report of a workshop.
2004
-
Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002.
2003
-
Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma..
41.
2023
-
You Get (offered) What You (can) Pay for: Explaining Disparities in End-of-Life Cancer Care.
2023
-
Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?.
41.
2023
-
Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes..
39.
2021
-
Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?.
38.
2020
-
Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon..
38.
2019
-
De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma..
37.
2019
-
Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors..
37.
2019
-
Risk-Imaging Mismatch: Why Is There a Disconnect?.
36.
2018
-
Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors..
35.
2016
-
Lenalidomide in Adult T-Cell Leukemia/Lymphoma..
34.
2016
-
Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer..
34.
2016
-
Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival?.
34.
2016
-
Evaluating Quality Metrics for the Care of Patients With Blood Cancer Who Are Near Death..
34.
2016
-
Targeting the Vascular Endothelial Growth Factor Pathway in Gastric Cancer: A Hit or a Miss?.
34.
2016
-
Lapatinib in Gastric Cancer: What Is the LOGiCal Next Step?.
34.
2015
-
One and Done: A Week of Radiotherapy for Glioblastoma..
33.
2015
-
Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This "Early Metabolic Look" Strategy?.
33.
2015
-
Tumor Genetic Screening Programs: A Call to Action..
33.
2015
-
Can money really be no object when cancer care is the subject?.
33.
2015
-
Failure of ELM-PC 5: an ineffective drug or an unfit end point?.
33.
2015
-
Markers for the early detection of prostate cancer: some principles for statistical reporting and interpretation..
32.
2014
-
Multigene panel testing: planning the next generation of research studies in clinical cancer genetics..
32.
2014
-
Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer..
32.
2014
-
Evolving treatment paradigms for primary mediastinal diffuse large B-cell lymphoma..
32.
2014
-
Take care of yourself: we need you..
32.
2014
-
Defining the role of laparoscopic gastrectomy for gastric cancer..
32.
2014
-
Allelic polymorphisms of inhibitory killer immunoglobulin-like receptor natural killer cell function can also influence the graft-versus-leukemia response..
31.
2013
-
Importance of genetics in the clinical management of chronic myelomonocytic leukemia..
31.
2013
-
Treatment of metastatic colon cancer: "the times they are A-changing"..
31.
2013
-
Evidence-based breast cancer screening guidelines for women who received chest irradiation at a young age..
31.
2013
-
Treatment-emergent effects may predict benefit from endocrine therapy..
31.
2013
-
The search for an elusive uniform strategy for a heterogeneous disease: lesson learned?.
31.
2013
-
Evolving panorama of treatment for metastatic pancreas adenocarcinoma..
31.
2013
-
Disparities in breast cancer outcomes: receipt of chemotherapy is only part of the story..
30.
2012
-
Graft-versus-host disease: have we solved the problem?.
30.
2012
-
Moving forward one Notch at a time..
30.
2012
-
Public health and the tanning bed controversy..
30.
2012
-
Refining the use of endocrine therapy for ductal carcinoma in situ..
30.
2012
-
Potential pitfalls of the rapid uptake of new technology in surgery: can comparative effectiveness research help?.
30.
2012
-
Off-label use of oncology drugs: the need for more data and then some..
30.
2012
-
The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research..
30.
2012
-
Factors dictating outcomes in patients with colorectal cancer and peritoneal carcinomatosis: selection, resection, or convection?.
30.
2011
-
Do women remain at risk even if they do not inherit a familial BRCA1/2 mutation?.
29.
2011
-
Therapy for pediatric brain tumors and the risk of growth hormone deficiency..
29.
2011
-
Virchow 2011 or how to ID(H) human glioblastoma..
29.
2011
-
No place like home? Outpatient management of patients with febrile neutropenia and low risk..
29.
2011
-
TACE and sorafenib: a good marriage?.
29.
2011
-
The end of an era: shall we move forward?.
29.
2011
-
Should the presence of germline BRCA1/2 mutations influence treatment selection in breast cancer?.
29.
2011
-
The study of collaborative practice arrangements: where do we go from here?.
29.
2011
-
Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?.
29.
2011
-
Prediction models: revolutionary in principle, but do they do more good than harm?.
29.
2011
-
Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy..
29.
2011
-
Cabozantinib in medullary thyroid carcinoma: time to focus the spotlight on this rare disease..
29.
2011
-
Rectal cancer trials: no movement..
29.
2011
-
Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift?.
29.
2011
-
How long is long enough?.
29.
2011
-
Big costs for little gain in ovarian cancer..
29.
2011
-
Carboplatin in clinical stage I seminoma: too much and too little at the same time..
29.
2011
-
Treatment of low-risk gestational trophoblastic neoplasia..
29.
2011
-
Denosumab: second chapter in controlling bone metastases or a new book?.
28.
2010
-
New pharmacogenomic paradigm in breast cancer treatment..
28.
2010
-
Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains..
28.
2010
-
A step forward for two-step screening for ovarian cancer..
28.
2010
-
Stereotactic body radiation therapy versus wedge resection for medically inoperable stage I lung cancer: tailored therapy or one size fits all?.
28.
2010
-
Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easy..
28.
2009
-
Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations..
28.
2009
-
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]..
27.
2009
-
Clinical dilemma of ductal carcinoma in situ..
27.
2009
-
More mastectomies: is this what patients really want?.
27.
2009
-
Epothilones: better or more of the same?.
27.
2009
-
Targeting renal cell carcinoma..
27.
2009
-
Chemotherapy alone for laryngeal preservation--is it possible?.
27.
2009
-
Bone marrow aspiration for disseminated tumor cell detection: a must-have test or is the jury still out?.
27.
2009
-
Progress in mantle-cell lymphoma..
27.
2008
-
The drama of the gifted disease..
27.
2008
-
Refractory thyroid cancer: a paradigm shift in treatment is not far off..
26.
2008
-
Individualized treatment selection in patients with head and neck cancer: do molecular markers meet the challenge?.
26.
2008
-
Combining a peptide vaccine with high-dose interleukin-2..
26.
2008
-
Stage I testicular cancer management and necessity for surgical expertise..
26.
2008
-
Practice-based evidence of the beneficial impact of positron emission tomography in clinical oncology..
26.
2008
-
Determinants of RASistance to anti-epidermal growth factor receptor agents..
26.
2008
-
Should intensity-modulated radiation therapy be the standard of care in the conservatively managed breast cancer patient?.
26.
2008
-
Magnetic resonance imaging in the breast cancer patient: curb your enthusiasm..
26.
2008
-
Time to check CHEK2 in families with breast cancer?.
26.
2008
-
The graying of testis cancer patients: what have we learned?.
25.
2007
-
Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?.
25.
2007
-
Skin squamous cell cancer: the time is right for greater involvement of the medical oncologist..
25.
2007
-
Surgery after primary chemoradiotherapy in squamous cancer of the esophagus: is the photon mightier than the sword?.
25.
2007
-
Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer..
25.
2007
-
Targeting HER2 in prostate cancer: where to next?.
25.
2007
-
Are nomograms better than currently available stage groupings for bladder cancer?.
24.
2006
-
Can granulocyte-colony stimulating factor worsen anemia?.
24.
2006
-
Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy..
24.
2006
-
Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted?.
24.
2006
-
Consolidation for ovarian cancer in remission..
24.
2006
-
Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphoma..
24.
2006
-
Induction chemotherapy for larynx preservation: patient selection or therapeutic effect?.
24.
2005
-
Mechanisms of late cardiovascular toxicity from cancer chemotherapy..
23.
2005
-
Carboplatin for stage I seminoma and the sword of Damocles..
23.
2005
-
Mediastinoscopy: an endangered species?.
23.
2005
-
Just when you thought the fluorouracil debate was over: S-1 and gastric cancer..
23.
2005
-
Lymphovascular invasion as an independent predictor of recurrence and survival in node-negative bladder cancer remains to be proven..
23.
2005
-
Treating cancer by blocking cell signals..
23.
2005
-
"Will weekly work"? Seems to be so.....
23.
2005
-
Distilling cancer biomarkers from the serum peptidome: high technology reading of tea leaves or an insight to clinical systems biology?.
23.
2005
-
Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?.
23.
2005
-
High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remission..
23.
2005
-
High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care..
23.
2005
-
MSH6 mutations in hereditary nonpolyposis colon cancer: another slice of the pie..
22.
2004
-
T-cell chauvinists versus antibody advocates--can't we all just get along?.
22.
2004
-
Toward a glioblastoma vaccine: promise and potential pitfalls..
22.
2004
-
Cancer screening: how good is good enough?.
22.
2004
-
Thin melanoma: still "excellent prognosis" disease?.
22.
2004
-
New target, new drug, old paradigm..
22.
2004
-
The phase III candidate: can we improve the science of selection?.
22.
2003
-
Primary central nervous system lymphoma: a curable brain tumor..
21.
2003
-
Topical ONYX-015 in the treatment of premalignant oral dysplasia: another role for the cold virus?.
21.
2003
-
Poor-risk testicular cancer and high-dose chemotherapy..
21.
2003
-
Why do we need another antiemetic? Just ask..
21.
2003
-
Another study of how to give fluorouracil?.
21.
2003
-
Advances in molecular staging of melanoma patients: multimarker analysis of archival lymph node tissue..
21.
2003
-
Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?.
21.
2003
-
Renal cell carcinoma: a priority malignancy for development and study of novel therapies..
21.
2003
-
How can we tell when cancer vaccines vaccinate?.
21.
2003
-
Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism?.
21.
2003
-
Taking stock of volume-outcome studies..
21.
2003
-
Primary central nervous system lymphoma: time to ask the question..
20.
2002
-
Vaccinating patients with autologous tumor..
20.
2002
-
Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor..
20.
2002
-
Comparing contemporary surgery to external-beam radiotherapy for clinically localized prostate cancer..
20.
2002
-
Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead?.
20.
2002
-
Cooling off hot flashes..
20.
2002
-
Prognostic factors for sarcomas: hard and soft..
20.
2002
-
Chemoprevention of breast cancer: a model for change..
20.
2002
-
High-dose chemotherapy for breast cancer: "how do you know?"..
19.
2001
-
Preoperative chemoradiotherapy for esophageal cancer..
19.
2001
-
Dendritic cells as immunologic adjuvants for the treatment of cancer..
18.
2000
-
Germ cell tumors: there is still plenty to learn..
16.
1998
-
Lung cancer cure, care, and cost: let the data be your guide..
15.
1997
-
Bleomycin in germ cell tumor therapy: not all regimens are created equal..
15.
1997
-
Selecting patients with cisplatin-resistant germ cell tumors for high-dose chemotherapy..
14.
1996
-
Chemotherapy for colorectal carcinoma: one small step forward, one step backward..
13.
1995
-
CNS leukemia: problem of diagnosis, treatment, and outcome..
13.
1995
-
Chemotherapy in acute myelogenous leukemia: high dose, higher expectations?.
13.
1995
-
Brain tumor chemotherapy trials: slow start, but quickly gaining..
12.
1994
-
Radiosurgery: a new application?.
10.
1992
-
The late effects of germ cell tumor chemotherapy: more data are needed..
10.
1992
-
Radiosurgery for malignant brain tumors..
8.
1990
-
Multimodality therapy of esophageal carcinoma: still an experimental approach..
5.
1987
-
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
2020
-
Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis.
2018
-
Locally Aggressive Connective Tissue Tumors.
2017
-
Integrating Evidence-Based Medicine for Treatment of Spinal Metastases Into a Decision Framework: Neurologic, Oncologic, Mechanicals Stability, and Systemic Disease.
2017
-
Obesity and Cancer Mechanisms: Cancer Metabolism.
2016
-
Structural Barriers to Diagnosis and Treatment of Cancer in Low- and Middle-Income Countries: The Urgent Need for Scaling Up.
2015
-
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
2015
-
Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape.
2015
-
Treatment of Brain Metastases.
2015
-
Advances and challenges in treatment of locally advanced rectal cancer.
2015
-
Update on metastatic gastric and esophageal cancers.
2015
-
Immune Checkpoint Blockade in Cancer Therapy.
2015
-
Dilemmas in treating smoldering multiple myeloma.
2014
-
Current state of the art and science of patient-clinician communication in progressive disease: patients' need to know and need to feel known.
2014
-
Breast and ovarian cancer in the older woman.
2014
-
Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors.
2014
-
Surgical considerations in older adults with cancer.
2014
-
Pain in cancer survivors.
2014
-
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
2013
-
Leveraging cancer genome information in hematologic malignancies.
2013
-
New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.
2013
-
Cancer- and cancer treatment-associated cognitive change: an update on the state of the science.
2012
-
Communication skills training for oncology professionals.
2012
-
Evidence-based treatment of delirium in patients with cancer.
2012
-
Targeting the interleukin-6/Jak/stat pathway in human malignancies.
2012
-
Thymic malignancies: from clinical management to targeted therapies.
2011
-
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.
2011
-
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.
2011
-
Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services.
2011
-
Unraveling the molecular pathophysiology of myelodysplastic syndromes.
2011
-
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
2010
-
Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.
2010
-
Role of adjuvant therapy after resection of colorectal cancer liver metastases.
2010
-
Are gold standard depression measures appropriate for use in geriatric cancer patients? A systematic evaluation of self-report depression instruments used with geriatric, cancer, and geriatric cancer samples.
2009
-
Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings.
2009
-
Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study.
2009
-
The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research.
2009
-
High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance.
2009
-
Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis.
2008
-
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
2008
-
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
2008
-
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
2008
-
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
2007
-
Long-term health status among survivors of childhood cancer: does sex matter?
2007
-
Immunologic approaches to ovarian cancer treatment.
2007
-
Organ preservation for rectal cancer.
2007
-
Chemotherapy for advanced germ cell tumors.
2006
-
Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.
2006
-
Targeted therapy for metastatic renal cell carcinoma.
2006
-
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
2006
-
Cancer genetic testing and assisted reproduction.
2006
-
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.
2005
-
Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.
2005
-
Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting.
2005
-
Genetics of myeloid malignancies: pathogenetic and clinical implications.
2005
-
Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
2005
-
Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.
2005
-
Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma.
2005
-
The theoretical basis of transcriptional therapy of cancer: can it be put into practice?
2005
-
Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma.
2005
-
Advances in breast conservation therapy.
2005
-
Lymphatic mapping and sentinel lymph node biopsy for breast cancer: developments and resolving controversies.
2005
-
Prevention and management of hereditary breast cancer.
2005
-
Hereditary cancer predisposition syndromes.
2005
-
Small-cell carcinomas of the gastrointestinal tract: a review.
2004
-
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.
2003
-
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.
2003
-
Detection and measurement of occult disease for the prognosis of solid tumors.
2003
-
Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement.
2001
-
Development of inhalational agents for oncologic use.
2001
-
How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
2001
-
Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review.
2000
-
Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review.
1998
-
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
1998
-
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997
-
International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review.
1996
-
Quantitating familial cancer risk: a resource for clinical oncologists.
1994
-
Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients.
1992
-
Health Care Transitions Among Adolescents and Young Adults With Cancer.
2024
-
Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis.
2022
-
Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma.
2022
-
Improving Male Reproductive Health After Childhood, Adolescent, and Young Adult Cancer: Progress and Future Directions for Survivorship Research.
2018
-
Models of Care for Survivors of Childhood Cancer From Across the Globe: Advancing Survivorship Care in the Next Decade.
2018
-
New Agents, Emerging Late Effects, and the Development of Precision Survivorship.
2018
-
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
2018
-
Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia.
2017
-
Primary CNS Lymphoma.
2017
-
Clinical and Technical Aspects of Genomic Diagnostics for Precision Oncology.
2017
-
Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration.
2015
-
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer.
2009
-
Role of anthracyclines in the treatment of early breast cancer.
2009
-
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
2007
-
Management of advanced prostate cancer after first-line chemotherapy.
2005
-
Intracellular signal transduction pathway proteins as targets for cancer therapy.
2005
-
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.
2005
-
When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer.
2001
-
Primary mediastinal B-cell lymphoma: a review of pathology and management.
2001
-
Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer.
2000
-
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
1998
-
Does tamoxifen cause cancer in humans?
1998
-
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
2018
-
Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline.
2017
-
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
2017
-
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
2016
-
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
2016
-
Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.
2014
-
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
2010
-
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
2006
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)